Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | IDO1 | P14902 | 3/20 | 0.48 |
| ▸ | AGXT | P21549 | 2/20 | 0.48 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | APP | P05067 | 7/20 | 0.45 |
| ▸ | PDE2A | O00408 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16614394 | 0.88 | L3MBTL1 (0.57) | TDP1L3MBTL1IDO1AGXTPYCR1 | |
| SCHEMBL5323565 | 0.87 | L3MBTL1 (0.60) | TDP1L3MBTL1IDO1AGXTPYCR1 | |
| SCHEMBL23015014 | 0.87 | L3MBTL1 (0.60) | TDP1L3MBTL1IDO1AGXTPYCR1 | |
| SCHEMBL23015037 | 0.84 | L3MBTL1 (0.57) | TDP1L3MBTL1IDO1AGXTPYCR1 | |
| SCHEMBL23014810 | 0.84 | L3MBTL1 (0.57) | TDP1L3MBTL1IDO1AGXTPYCR1 | |
| SCHEMBL25372049 | 0.84 | L3MBTL1 (0.57) | TDP1L3MBTL1IDO1AGXTPYCR1 | |
| SCHEMBL8499580 | 0.82 | IDO1 (0.61) | TDP1L3MBTL1IDO1AGXTCA1 | |
| SCHEMBL3803477 | 0.81 | IDO1 (0.52) | TDP1L3MBTL1IDO1AGXTPYCR1 | |
| SCHEMBL13278307 | 0.81 | TDP1 (0.49) | TDP1L3MBTL1IDO1AGXTCA1 | |
| SCHEMBL20569054 | 0.79 | L3MBTL1 (0.51) | TDP1L3MBTL1IDO1AGXTCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2308861-B1 | MACROCYCLIC COMPOUNDS USEFUL AS PHARMACEUTICALS | EISAI R&D MAN CO LTD (JP) | 2017-03-01 | — | — | EP | disclosed |
| US-7915306-B2 | For therapy of inflammatory or autoimmune disorders | EISAI CO., LTD. (JP) | 2011-03-29 | — | — | US | disclosed |
| US-7799827-B2 | Macrocyclic compounds useful as pharmaceuticals | EISAI CO., LTD. (JP) | 2010-09-21 | — | — | US | disclosed |
| US-20050239804-A1 | Method for improved chemical synthesis of guanidinium alkaloids | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2005-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239804-A1 | Method for improved chemical synthesis of guanidinium alkaloids | PAICS, TYMS, IMPDH1 | TDP1 904/4885L3MBTL1 2014/4885IDO1 379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.